Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Nephros (NEPH) over the last 8 years, with Q3 2025 value amounting to $160843.0.

  • Nephros' Gains from Sales and Divestitures changed N/A to $160843.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $160843.0, marking a year-over-year change of. This contributed to the annual value of $42167.0 for FY2024, which is 7751.13% down from last year.
  • As of Q3 2025, Nephros' Gains from Sales and Divestitures stood at $160843.0.
  • In the past 5 years, Nephros' Gains from Sales and Divestitures registered a high of $187503.0 during Q4 2023, and its lowest value of $23781.0 during Q4 2021.
  • Over the past 5 years, Nephros' median Gains from Sales and Divestitures value was $58961.0 (recorded in 2025), while the average stood at $94871.6.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 9995.68% in 2021, then soared by 31916.97% in 2023.
  • Nephros' Gains from Sales and Divestitures (Quarter) stood at $23781.0 in 2021, then soared by 88.1% to $44732.0 in 2022, then surged by 319.17% to $187503.0 in 2023, then plummeted by 77.51% to $42167.0 in 2024, then skyrocketed by 281.44% to $160843.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $160843.0 for Q3 2025, versus $146114.0 for Q2 2025 and $58961.0 for Q1 2025.